Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Harpoon Therapeutics closes $70mm Series C

Executive Summary

Immunotherapy firm Harpoon Therapeutics Inc. raised $70mm through its Series C round. Lead investor OrbiMed was joined by other new investors Cormorant, Ridgeback Capital, Lilly Asia Investments, and NS Investment, along with returning backers MPM Capital, Oncology Impact Fund (under MPM), Arix Bioscience (invested $8mm and retains its 11.3% stake), New Leaf Venture Partners, and Taiho Ventures. Proceeds will support advancement of candidates discovered with the company's TriTAC (Tri-specific T cell Activating Construct) and ProTriTAC (Protease-activated Tri-specific T Cell Activating Construct) platforms, including HPN424 (Phase I for prostate cancer) and preclinical projects HPN536 (mesothelin-expressing tumors) and HPN217 (multiple myeloma).
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies